Convulsive status epilepticus (CSE) is a medical emergency associated with high mortality and morbidity. The most recent definition of CSE is a convulsive seizure lasting more than 5 min or consecutive seizures without recovery of consciousness. In adults, for the treatment of the early stages of CSE, diazepam, lorazepam or midazolam are the most common treatments, although the choice of agent seems less important than rapid treatment. Midazolam, when administered intramuscularly (best evidence), buccally, or nasally, is effective and safe in the pre-hospital setting.
Introduction
Status epilepticus (SE) is the second-most common neurologic emergency with an annual incidence of 10-41 cases per 100,000 population [1] [2] [3] .
Convulsive subtype, which is the most severe, accounts for 45%-74% of all cases of SE [4] , is associated with a mortality ranging from 7.2% to nearly 20% [3, 5, 6] . Its clinical presentation is characterized by impairment of consciousness and prominent motor symptoms (episodes of excessive abnormal muscle contractions, usually bilateral, which may be interrupted or sustained) [7] . There is evidence that a long duration of convulsive SE (CSE) is associated with a worst prognosis, also because it becomes less responsive to treatment. It has been demonstrated that ongoing seizure activity makes GABAergic drugs less effective because of the internalization of GABA receptors [8] . Other factors including the upregulation of drug-efflux transporters such as P-glycoprotein or an increased secretion of pro-inflammatory agents [9] might also determine a reduced drug response in SE.
The International League Against Epilepsy (ILAE) recently defined SE as follows: a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t 1). It is a condition that can have longterm consequences (after time point t 2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures [7] . For CSE, time point T1 has been set at 5 min, since after this time, it is likely that a seizure will continue if not treated. T2 is 30 min, which is the time after which there is a risk of long-term consequences [9, 10] .
According to the duration and drug response, CSE may be divided into different stages which differ in terms of the sensitivity to the drugs used, the need for different treatments and also the different morbidity and mortality. This review provides an overview of the treatment of all different stages of CSE in adults using currently available clinical data. A PubMed literature search was performed for relevant articles describing human subjects and published in the English language up to October 2016, using the following terms: status epilepticus, refractory seizures, and individual anti-seizure treatments. Table 1 presents a treatment algorithm with details on drug doses used in the various stages Table 2 presents the most important pharmacological characteristics of the drugs used in this condition.
Treatment phases of convulsive status epilepticus

Pre-hospital management
Stage 1 (early or impending CSE)
This is a condition in which only a few minutes have elapsed from the beginning of convulsions. Benzodiazepines, which enhance the neurotransmission of GABA at the GABA A receptor, are the drugs of choice [4] . Intravenous (IV) lorazepam is most commonly used, although, more recently, midazolam for intramuscular (IM), nasal or buccal injection was found to have a similar efficacy and is easier to administer [11] . Unfortunately, in several countries this drug has still not been authorized for use in this condition in adults [12] . Diazepam for rectal and, possibly, nasal administration has also been used [13] . Sedation and respiratory depression are the most common adverse effects of benzodiazepines [14] .
In a recent double-blind study carried out in the pre-hospital setting called RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial), patients with CSE randomized to 10 mg of IM midazolam had a better outcome than those randomized to 4 mg of IV lorazepam in spite of the longer time required for therapeutic serum concentrations and the therapeutic effect for IM midazolam [15] . This difference was interpreted as being due to the time required to obtain IV access. In a secondary analysis limited to paediatric patients, both treatments were equally effective [11] .
A network meta-analysis comparing 16 randomised clinical trials of non-venous drug treatments for acute convulsive seizures and convulsive status epilepticus, showed that IM midazolam is superior to other nonvenous medications [16] . This analysis also demonstrated that intranasal midazolam was effective for seizure cessation within 10 min of administration [15] . Further indirect comparison meta-analyses have shown that intranasal and buccal midazolam share a similar efficacy in the treatment of early SE in children [17] . In addition these meta-analyses showed that non-IV midazolam is as effective and safe as intravenous or rectal diazepam in terminating early SE in children [18] although there is no evidence of the superiority of IV lorazepam over IV diazepam [19] . A practical consideration favouring the use of midazolam is that lorazepam but not midazolam, has a poor stability in unrefrigerated conditions [20] . Recent guidelines state that IM midazolam has a superior effectiveness compared to intravenous lorazepam in adults with CSE without established intravenous access (Level A) [21] . Finally, a prospective observational study comparing the efficacy of clonazepam, lorazepam or midazolam as a first-line CSE treatment, found that clonazepam was associated with a similar efficacy to lorazepam [22] . At this stage, although treatment with benzodiazepines is sometimes continued as an infusion, the vast majority of authors recommend starting IV infusion of an antiepileptic drug (AED). In a prospective randomized controlled trial, the relative efficacy and safety of IV valproate or continuous diazepam infusion as secondline anticonvulsants were evaluated. Although both medications were found to be equally effective, tolerability (hypotension, respiratory depression and need for vasopressor support) was worse with diazepam [23] . In terms of their tolerability profile, benzodiazepines are usually not considered as second-line drugs for the treatment of CSE.
Phenytoin (fosphenytoin in the USA) is still most commonly used, mainly because of the familiarity with its use as well as its long half-life. Today, at least four other drugs should be considered as second-line agents following benzodiazepine: valproic acid, levetiracetam, phenobarbital and, more recently, lacosamide [10] .
In clinical practice guidelines from the European Federation of Neurological Sciences (EFNS) released in 2010, phenytoin was still recommended as the standard first-line agent for the management of CSE in this stage [24] . However, in more recent clinical practice guidelines from the Neurocritical Care Society and the American Epilepsy Society [25] , published in 2012, this was questioned. In these latter guidelines, evidence of efficacy included: valproate, class IIa, evidence level A, phenytoin, class IIa, level B, and levetiracetam class IIb, level C [25] . Interestingly, a survey of experts [26] showed that the selection of the agent for the secondline treatment of CSE, is driven by the individual patient's characteristics and includes three drugs: phenytoin/fosphenytoin, valproate sodium, and levetiracetam.
In 2013, a descriptive meta-analysis of drugs used as the second-line treatment of CSE was published [27] . Twenty-two, mostly non randomized studies, were identified, which assessed five drugs: phenobarbital, phenytoin, levetiracetam, lacosamide and valproate in patients who had a CSE (almost all cases) that had failed to respond to a benzodiazepine. Although heterogeneity and possible sources of bias due to the different characteristics of the patients and methods of assessment weaken the results of the meta-analysis, and the efficacy of these drugs was not significantly different, it is worth mentioning that valproate was effective (cessation of seizure activity) in 75.7% of cases, phenobarbital in 73.6% and levetiracetam in 68.5%, while phenytoin showed the lowest mean efficacy of 50.2%. There were insufficient data for the efficacy assessment of lacosamide. Recently, in a randomized study performed in India, 150 adult subjects with established CSE (CSE not controlled by lorazepam), were randomized to phenytoin, valproate and levetiracetam, and no significant differences were observed between these drugs, with success rates of 68%, 68% and 78%, respectively [28] . For a comparison between levetiracetam, valproic acid and phenytoin, one retrospective study showed that levetiracetam was significantly less effective than valproate and phenytoin [29] .
In recent years, several case reports [30] and small retrospective studies with heterogeneous case series [31] [32] [33] have highlighted the efficacy of lacosamide in this stage, however no precise information can be drawn because this agent had been administered at least in some patients, after a second line AED [31] .
In conclusion, we should acknowledge that several methodological problems hamper an assessment of the comparative efficacy of drugs used for the treatment of established CSE, much more than the comparison of first-line treatments. In established CSE, case series are more heterogeneous, and also the assessment of results seems to be more influenced by the different outcome measures adopted in the various studies [34] . In future studies, efficacy criteria for the analysis of AEDs in the treatment of established CSE should be standardized and a sufficient number of patients should be recruited [35] . In the meantime, safety, tolerability and ease of use of each individual drug should be considered first in the selection of the most appropriate AED in this stage of CSE. 
Stage 1
Benzodiazepines enhance neurotransmission of GABA at the GABA A receptor, increasing the frequency of chloride ion channel opening in response to GABA. Diazepam rapidly penetrate the blood-brain barrier, resulting in a rapid onset of action. However, as a result of its lipophilic nature, it also rapidly redistributes from the brain to other lipophilic tissues in the body, which determine the relatively short duration of the antiseizure effect after IV administration [73] .
Lorazepam has a slower onset of action due to a lower entry of this agent into the brain but has a longer anticonvulsant action than diazepam [74] .
Midazolam has a relatively short half-life after a single dose. A significantly increased half-life may be observed after prolonged infusion [75] . Drug metabolism includes hydroxylation from CYP 3A4 and 3A5 [76] . Levels of midazolam are affected by enzyme inducing AEDs and by other medications that are inducers or inhibitors, particularly during continuous infusion [77] . Adverse effects are similar for all benzodiazepines and include sedation, dizziness, weakness, unsteadiness, respiratory depression, and hypotension. There are additive effects when several benzodiazepines are co-administered.
Stage 2
Valproate prolongs sodium channel inactivation, attenuates calcium mediated transient currents and augments GABA. Target levels: 75-100 mg/L. It is a cytochrome P450 inhibitor, thus interacting with many medications [78] . Main adverse effects: hepatotoxicity, thrombocyte dysfunction, hyperammonemia, and acute hemorrhagic pancreatitis [79] . Valproate may be dangerous in patients with mitochondriopathy [80] .
Levetiracetam modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain. It does not affect the cytochrome P450 enzymes [80] . It has a good tolerability profile.
Phenytoin blocks voltage gated sodium channels. It has a worse than valproate and levetiracetam side-effect profile and several drug-drug interactions (cytochrome P450 inducer). Two hours after the loading dose, phenytoin drug levels should be checked [10] . Target level: 15-20 mg/L. Blood pressure and electrocardiographic monitoring is needed. Caution in patients with AV block, atrial fibrillation and atrial flutter. PR interval should be <200 ms. [10] . Adverse effects: Hypotension, bradycardia, sino-atrial block, second-and third-degree atrio-ventricular block, severe tissue necrosis after paravenous infusion [10] . A black box warning exists for cardiovascular risk with rapid infusions.
Lacosamide is a functionalized amino acid that enhances slow inactivation of voltage-gated sodium channels. Caution in patients with AV block, atrial fibrillation and atrial flutter. It has a relatively good tolerability profile.
Phenobarbital has been used in the past as a second or even a first line agent. It may cause respiratory depression and is a strong enzyme inducer which increases the rate of metabolism of several drugs. Its efficacy has been demonstrated [81] .
Stage 3
Midazolam, for the mechanism of action and kinetic see above.
During continuous infusion, tachyphylaxis, may necessitate progressively higher doses. At doses used in stage 2-3 it causes respiratory depression, requiring intubation for the duration of therapy. Propofol has ultra-fast onset and rapid clearance even after extended infusion [82] . It is metabolized primarily through hepatic glucuronidation with subsequent renal excretion, though a significant portion is also metabolized by cytochrome P450 isozymes [54] . Propofol is not indicated in young children [39] . Monitor lactate, creatine kinase, triglycerides, and potassium in prolonged use. Adverse effects: hypotension (may require vasopressors), respiratory depression, and bradycardia. Hypertriglyceridemia is common (its formulation is a lipid emulsion). Propofol-related infusion syndrome (PRIS: severe metabolic acidosis, rhabdomyolysis, renal failure, and circulatory collapse), is most often observed in children, but has also been associated with prolonged infusions in refractory CSE in adults [83] . Thiopental has a nonlinear metabolism and a long half-life (ranging from 11 to 36 h) [84, 85] . Autoinduction of its metabolism, which typically takes days to occur, is observed as well as several drug interactions. Hepatically metabolized and highly protein-bound in plasma [86] . Therapeutic monitoring of pentobarbital levels should not be used to guide therapy for refractory CSE [39] . Adverse effects: hypotension, cardio-respiratory depression; and pancreatic and hepatic toxicity. Ketamine may be used in conjunction with another anaesthetic, preferably one with GABAergic action. It has high lipid solubility leading to a fast onset and extensive distribution, with an elimination half-life of around 2-3 h. Metabolised by the cytochrome P450 system (especially CYP3A4) into the active metabolite norketamine [87] . Not associated with cardiac depression and hypotension or respiratory depression. Induces a positive sympathetic response, sometimes leading to drug-induced hypertension. Dangerous in patients with coronary disease or cardiomyopathy. Adverse effects: possible increase in intracranial pressure [39, 51] . Hypersalivation may be relevant. Agitation, confusion, and psychosis may be observed after ketamine is stopped.
When no otherwise specified, data are from Meldrum [88] ; Falco Wolter and Bleck [10] ; Reznik et al. [39] ; Brophy et al. [25] .
2.3. Hospital management in the intensive care unit 2.3.1. Stage 3 (refractory CSE): CSE persisting after second-line treatments Between 23-44% of patients with CSE still have seizures after second -line treatments and therefore, 60 min after the administration of these agents, should be considered as affected by refractory CSE [36] [37] [38] [39] . Electroencephalography (EEG) with clinical examination may be necessary to determine the persistence of CSE at this stage. Neurocritical Care Society and American Epilepsy Society guidelines recommend immediately starting anaesthetic agents in combination with critical care treatments [25] . In the meantime repeating additional doses of previously administered second-line AEDs may be considered (see Table 1 ). At this stage, CSE mortality has been calculated to vary between 16% and 39% [40] .
The most commonly used agents are midazolam, propofol, and thiopental (pentobarbital in USA), which are given as bolus and/or continuous infusions. Bolus doses can be added for breakthrough seizures [38] . A fourth anaesthetic, ketamine, has also been increasingly described for the treatment of this condition [37, 38] .
At this stage, the goal of total seizure suppression cannot be achieved without inducing a therapeutic coma, and the intensity of treatment is usually dictated by the cessation of electrographic seizures or by a burst suppression pattern on the electroencephalogram (EEG) [25] . However, there is no clear finding that therapeutic coma reduces mortality [41] . In addition, there is evidence that patients with SE who receive anaesthetics have a higher proportion of infection and an increased risk of death compared to patients not receiving this treatment [42] .
In a narrative meta-analysis of 28 open studies, it emerged that titration of the anaesthetic agent to EEG background suppression was associated with a significantly lower frequency of breakthrough seizures than titration to seizure suppression, however this was also associated with a significantly higher frequency of complications (mainly hypotension). The choice of anaesthetic on the other hand, did not seem to influence immediate treatment failure and mortality [43] .
Only one comparative, single blind, randomized, multi-center trial compared two anaesthetic agents (propofol and barbiturates) in the treatment of refractory CSE in adults [44] . Although 150 patients would have been randomized, this trial was terminated after 3 years, with only 24 patients recruited, which demonstrates the difficulty in conducting randomized trials in this condition. No difference was observed between the two drugs, although barbiturate were associated with a significantly longer mechanical ventilation.
In a retrospective case series of 49 consecutive episodes of refractory CSE which were treated with barbiturates, propofol or midazolam, it was concluded that the outcome was independent of the specific coma-inducing agent used and the extent of EEG burst suppression [45] .
There have been no prospective comparative trials for midazolam, however a study was performed in which high and low doses of this drug were compared [46] . Patients treated with high doses (2.9 mg/kg/h) had fewer withdrawal seizures after weaning midazolam infusion and a significantly lower mortality. Since in refractory CSE, due to the internalization of GABA receptors, benzodiazepines are ineffective or have a low efficacy, there is no clear explanation for the effect of midazolam in this stage and it may be due to a still unknown mechanism of action.
Several case series of patients treated with propofol have been described, with generally favourable findings [47] [48] [49] [50] .
Ketamine is the fourth and least used anaesthetic agent for the treatment of refractory CSE. A retrospective review of medical records of 60 episodes of refractory CSE treated with this drug, revealed that ketamine was believed to have contributed to the permanent control of CSE in 32% of cases, although this drug had often been added after other unsuccessful anaesthetic agents [51] . It has been suggested that the efficacy of this drug may be higher if introduced earlier [34] .
Due to the lack of sufficiently powered randomized studies, a registry was developed in which patients who required general anaesthesia for the control of SE could be prospectively included [52] . Of the 488 cases registered, the most widely used anaesthetic of first choice was found to be midazolam (59%), followed by propofol and barbiturates. The anaesthetic agents most often used after failure of a first anaesthetic agent were barbiturates followed by midazolam. Ketamine was used in most severe cases, always as a second, third, or fourth choice.
At this stage, guidelines traditionally recommend continuing anaesthetic infusion for 24-48 h, followed by a gradual weaning off the infusion [25, 38] . Should seizures recur, an anaesthetic agent infusion is resumed often at a higher dose [25] .
In these patients, AEDs administered intravenously, through a nasogastric tube or percutaneous endoscopic gastrostomy, should be given in all cases, so that when the anaesthetic agent is withdrawn, there is adequate antiepileptic cover [53] . There are no data suggesting that any specific AED may be more indicated than another. In a review of the literature, the AEDs most often used in these circumstances were in the following order: topiramate, levetiracetam, lacosamide and pregabalin [53] . It has been claimed that weaning off thiopental (or pentobarbital) is associated with a lower incidence of recurrence when phenobarbital is added before weaning [38] . In the absence of any literature evidence, experts suggest avoiding more than 2 drugs, to avoid frequent switches, as rapid withdrawal can facilitate rebound seizures. On the other hand, a rapid titration may facilitate allergic reactions. In order to avoid drugs with a primarily GABAergic mechanism, drugs with multiple mechanisms of action are recommended, with low interaction potential and predictable kinetics [53] . Recently, a new CSE stage was proposed for patients who are not controlled by third-line anaesthetic compounds. Superrefractory CSE has been defined as CSE that persists or recurs for 24 h or more following a first course of anaesthetics for therapeutic coma induction, and includes those cases in which CSE recurs on the reduction or withdrawal of anaesthesia [58, 59] .
Approximately 10-15 10-15% of all patients presenting to hospital with CSE develop super refractory CSE [53] , although in a recent retrospective study, a lower proportion of 4% was reported [60] . In a retrospective analysis of a cohort of patients with CSE admitted to a neurointensive care unit, super refractory CSE was most often associated with encephalitis [61] .
Short-term mortality is higher in super-refractory CSE than that observed in refractory CSE [62] .
This condition has been mainly described in two clinical scenarios: 1) after a severe brain injury, 2) without any apparent cause in patients with no history of epilepsy (new-onset refractory status epilepticus-NORSE) [63] [64] [65] . Patients with NORSE, are frequently young [66] .
With the use of EEG, in these patients anaesthetic treatment should be titrated to burst suppression, targeting an interburst interval of about 10 s for 24 h [22] . However more recently the amount of epileptiform activity in bursts was found to correlate with success or failure to be weaned off anaesthetic treatment [67] . Anaesthesia can be reversed every 24-48 h and be re-established if seizures reoccur. In patients who are in a coma state, seizures are usually non convulsive, and the only way to assess seizure recurrence is with an EEG [25] . Cycles of anaesthesia should be repeated and, if CSE continues to recur, often in the form of "subtle" SE, the duration of individual cycles should be increased and anaesthesia continued for up to 5 days at a time [38] . The risk of complications of these procedures should be weighed in the individual patient.
In patients who do not respond to continuous infusion of a first anaesthetic, the dose should be increased or another agent should be started [38] .
Ketamine is a second-line anaesthetic agent which increases blood pressure, and thus may counteract the hemodynamic side effects of other anaesthetic infusions. Very recently, a retrospective analysis was published of 67 patients with super-refractory CSE who received both propofol and ketamine with good results [68] .
Recently, NORSE, which accounts for approximately 40% of refractory CSE cases, was shown to be autoimmune or paraneoplastic in nature in several cases [69, 70] . Early immunomodulatory treatments are thus increasingly becoming the mainstay of treatment, in addition to traditional anti-epileptic agents [65, 71] . Therapy with high-dose steroids and a course of intravenous immunoglobulin or plasma exchange is usually started (see Table 3 ).
Hypothermia has been used in a few cases, although there is a very low evidence of efficacy in this condition [72] . Deep levels may be unsafe [25, 42] . Finally, there is also low efficacy evidence for other treatments such as a ketogenic diet, or magnesium or pyridoxine infusions [53] . In rare cases, good long-term effects have been reported with neurosurgery, including focal resection, multiple subpial transection, corpus callosectomy or hemispherectomy [53] .
Conclusions
The treatment of CSE is still challenging. Almost all evidence of efficacy regards the early stages of this serious and life-threatening condition. In the most severe forms, all treatment decisions are only based on case series and expert opinions.
Here we summarise the most important findings in the field:
1) In the early stages, the most important issue is time. In the prehospital setting, IM midazolam may be preferable due to the rapidity of administration which offsets the faster effect of IV formulations [15] . 2) In stage 2, established status epilepticus, phenytoin can no longer be considered as the first choice. While phenytoin does not seem more effective, and perhaps is less effective than valproate, it is certainly associated with several risks and is not easy to administer [26, 27] . It requires a loading dose and a slow infusion rate with a consequent delay in the onset of action. A further disadvantage which needs emphasizing, is that this drug is an enzymatic inducer which may have serious consequences particularly in patients who need other drugs whose metabolism may be induced, such as midazolam, corticosteroids and other immunosuppressive agents [89] . The Established Status Epilepticus Treatment Trial (ESETT), which is currently enrolling patients, is in the process of comparing the three most commonly used agents (valproate, phenytoin, and levetiracetam) and will hopefully provide important information on this point [90, 91] . 3) In stages 3 (refractory CSE), and 4 (super-refractory CSE), thiopental or pentobarbital (in the USA) are strong inducers which may affect several treatments [39] . They also have a long half-life, a lot of adverse effects [39, 41] and, where possible, should be avoided. From a theoretical point of view, a combination of ketamine with midazolam or propofol [39] , might also be interesting to assess in randomized studies. 4) Finally, in refractory CSE and super-refractory CSE, particularly when these serious conditions appear in non epileptic subjects (NORSE) with no apparent cause for this condition, an autoimmune CSE should be suspected [59, 65] . In these cases, even without finding positive antibodies, it might be appropriate to start immunosuppressive treatments (corticosteroids and IV immunoglobulins). However it should be also taken into account that these conditions may not be responsive to firstline drugs and that in some cases, also second-line immunosuppressive agents might be required such as cyclophosphamide, rituximab [92, 93] or even cyclosporine A, tacrolimus and other immunosuppressants [94, 95] .
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Immunomodulatory agents Newly onset refractory status epilepticus (NORSE) is a condition which may be caused by autoimmune mechanisms.
In the case status epilepticus is refractory to anticonvulsants and there is no other known cause, the inflammatory nature of CSE should be explored trough neuroradiological examinations (cerebral MRI), and the search for inflammatory markers in the cerebrospinal fluid. Furthermore, the search for autoantibody in liquor and blood should be undertaken [92] . Diagnosis of autoimmune SE is now feasible with antibody tests although in several cases, these tests are not readily available and, in the case of negative findings of such tests, this diagnosis is not excluded. In those cases where this suspect is clinically justified, empiric immunomodulatory therapy may be recommended [71, [92] [93] [94] [95] . Corticosteroids IV methylprednisolone: 1 g daily for 5 days then weekly for 4-6 weeks AND/OR IV immunoglobulins: 0.4 g/kg daily for 3-5 days, then weekly for 4-6 weeks OR Plasmapheresis In the case of positive response consider chronic immunosuppression (mycophnolate mofetil or azathioprine) Second line immunosoppressive agents Antibody antagonists are increasingly used, often in association with other immunosuppressant agents. Rituximab (375 mg/m 2 every week for 4 weeks) is the most used. Natalizumab and tocilizumab have also been used.
Immunosuppressants: cyclophophamide (750 mg/m 2 ), given with the first dose of rituximab, followed by monthly cycles. Tacrolimus or cyclosporine A are also used [93, 94] .
